Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire August 2, 2022

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022

GlobeNewswire July 5, 2022

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)

GlobeNewswire July 5, 2022

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

GlobeNewswire May 24, 2022

Chinook Therapeutics Announces Proposed Public Offering

GlobeNewswire May 24, 2022

Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022

GlobeNewswire May 20, 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

GlobeNewswire May 19, 2022

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 12, 2022

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 12, 2022

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress

GlobeNewswire May 2, 2022

Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 25, 2022

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

GlobeNewswire April 12, 2022

Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 5, 2022

Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care

GlobeNewswire April 5, 2022

Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors

GlobeNewswire March 21, 2022

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 17, 2022

Chinook Therapeutics to Present at Oppenheimer's 32nd Annual Healthcare Conference

GlobeNewswire March 8, 2022

Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit

GlobeNewswire February 22, 2022

Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022

GlobeNewswire February 18, 2022

Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 9, 2022